Pharmacy Services

| EXTERNAL WEBPAGE MASTER FORMULA | | | | | |
|--|----------------------------|---|--|--|--|
| Compound Name: Vorinostat | | Container-closure system(s): Amber glass bottle | | | |
| Strength: 50 mg/mL | | Preservatives: Contained in suspending agent or sweetener | | | |
| Dosage Form: Oral Suspension | | Beyond Use Date (compound type): 35 days | | | |
| Product Description: Opaque suspension | | Storage: Refrigerate (preferred) or Room Temperature | | | |
| Auxiliary Labels: | | | | | |
| ☐ Take with food | Shake Well | \Box For external use only | | | |
| ☐ Refrigerate | \square Do not use after | \Box Do not take with dairy products | | | |
| ☐ Do not refrigerate | \square For the Ears | ☐ Avoid prolonged sun exposure | | | |
| ☐ Take even if you feel fine | \square For the Eyes | ☐ Other: Antineoplastic | | | |
| Quality control procedures (ex: pH test, etc.): Visual inspection of final product | | | | | |
| Ingredients: | | | | | |
| | | | | | |
| Vorinostat 100 mg capsules | | | | | |
| Ora Plus | | | | | |
| Ora Sweet (QS) | | | | | |
| | | | | | |
| | | | | | |

Instructions for preparation:

Directions:

- 1. Add the Ora-Plus into an amber glass bottle.
- 2. Place the contents of the Vorinostat 100 mg capsules in the same bottle and shake to disperse. (Shaking may take up to 3 minutes).
- 3. Once dispersed, add the Ora-Sweet to achieve the desired total volume. Shake again to disperse.

Calculations:

| Ingredient Name/Strength/Form | QS | Quantity | Units |
|----------------------------------|----|----------|----------|
| Vorinostat 100 mg capsule | | 20 | capsules |
| Ora Plus | | 20 | mL |
| Ora Sweet | X | 40 | mL |

Equipment/ Supplies:

| ☑ Mortar and Pestle | ☑ Stirring rod | ☐ Ointment slab |
|-------------------------|----------------|-----------------|
| ☐ Graduated cylinder(s) | ☐ Spatula | ☐ Balance |

Revised: TS 10/25



Pharmacy Services

| ☐ Weigh paper | | ☐ Ointment jar |
|-----------------|------------------|---------------------|
| ☑ Counting tray | ☐ Syringe (Oral) | ☑ Biological Safety |
| | Cabinet | |

References:

- 1. Fouladi M, Park JR, Stewart CF, et al. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol. 2010;28(22):3623–3629. doi:10.1200/JCO.2009.25.9119
- 2. US Pharmacopeial Convention, Inc. United States Pharmacopeia 42. Chapter <795> "Pharmaceutical Compounding-Non- Sterile Preparations." Rockville, MD: US Pharmacopeial Convention, Inc.; 2022.

Nationwide Children's Hospital Disclaimer:

The information provided on this site is for educational and informational purposes and may not be relied upon to direct or provide care to a patient. This material is not intended as a substitute for consulting health care professionals. The health care professionals remain solely responsible to provide and direct patient care. The information contained on this site may not be up to date due to more recent medical developments. The preparation, dispensing, and administration of pharmaceuticals is and remains the responsibility of licensed medical professional or pharmacist. Nationwide Children's Hospital assumes no liability for any injury and/or damage to persons from use of any information contained on this site.

Revised: TS 10/25

